Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a daily pill reach the brain to calm progressive MS?

NCT ID NCT07840326

Disease control Sponsor: Sundance Biosciences, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 25, 2026 · Last updated Sep 25, 2026

Summary

Researchers are testing an experimental daily pill called SUN-627 in adults aged 18 to 70 with non-active progressive multiple sclerosis, a form of MS where disability steadily worsens without relapses. The phase 2a trial aims to see whether the drug is safe and tolerable, how the body processes it, and whether it affects markers of brain inflammation. About 20 participants will receive either SUN-627 or a placebo for comparison.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SUN-627, an experimental once-daily oral tablet
What this could lead to
If SUN-627 proves safe and reaches the brain, it could offer a new oral option for progressive MS, a form of the disease with few treatments.
What could go wrong
This is a small, early-stage trial of 20 people, so it may not show a clear benefit or may reveal side effects. Results in this group may not apply to everyone with progressive MS.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18-70, inclusive 2. Diagnosis of PPMS or non-active SPMS 3. No MS relapses in the past 2 years 4. Evidence that MS has continued to get worse over time 5. A level of disability that fits the study requirements Exclusion Criteria: 1. Use of certain medications or treatments before the study, or need for these treatments during the study 2. Current participation in another research study 3. Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk 4. Certain serious or unstable medical conditions that could make the study unsafe 5. Active infection, recent infection, or a history of repeated infections Additional inclusion and exclusion criteria are outlined in the full study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-active secondary progressive multiple sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis demyelinating disease multiple sclerosis Neuroinflammatory Diseases primary progressive multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-active secondary progressive multiple sclerosis Non-active SPMS Primary progressive MS Primary progressive multiple sclerosis Primary progressive multiple sclerosis (PPMS) Secondary progressive MS Secondary progressive MS (SPMS) Secondary progressive multiple sclerosis (SPMS) Secondary progressive multiple sclerosis with inflammatory disease activity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    3 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Local Institution - Site 101

    RECRUITING

    Raleigh, North Carolina, 27607, United States

  • Local Institution - Site 102

    RECRUITING

    Atlanta, Georgia, 30309, United States

  • Local Institution - Site 104

    RECRUITING

    Columbus, Ohio, 43235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.